These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 8283826)

  • 21. Calcium ions inhibit the allosteric interaction between the dihydropyridine and phenylalkylamine binding site on the voltage-gated calcium channel in heart sarcolemma but not in skeletal muscle transverse tubules.
    Murphy BJ; Tuana BS
    Can J Physiol Pharmacol; 1990 Nov; 68(11):1389-95. PubMed ID: 1962734
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vanidipinedilol: a vanilloid-based beta-adrenoceptor blocker displaying calcium entry blocking and vasorelaxant activities.
    Yeh JL; Liou SF; Liang JC; Huang YC; Chiang LC; Wu JR; Lin YT; Chen IJ
    J Cardiovasc Pharmacol; 2000 Jan; 35(1):51-63. PubMed ID: 10630733
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activity of dihydrothienopyridine S312 enantiomers on L-type Ca2+ channels in isolated rat aorta and cerebral microvessels.
    Dessy C; Salomone S; Morel N; Godfraind T
    Eur J Pharmacol; 1993 Feb; 231(3):435-42. PubMed ID: 8449235
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MPC-1304, another type of dihydropyridine, possessing highly potent vasodilating action.
    Miyoshi K; Kanda A; Miyake H; Ichihara K; Kamei H; Nagasaka M
    Eur J Pharmacol; 1993 Jul; 238(2-3):139-48. PubMed ID: 7691619
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacological properties of voltage-dependent calcium channels in functional microvessels isolated from rat brain.
    Morel N; Godfraind T
    Naunyn Schmiedebergs Arch Pharmacol; 1989 Oct; 340(4):442-51. PubMed ID: 2555723
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Binding of the dihydropyridine calcium channel blocker (+)-[3H] isopropyl-4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-5-methoxycarbonyl-2, 6-dimethyl-3-pyridinecarboxylate (PN200-110) to RINm5F membranes and cells: characterization and functional significance.
    Yaney GC; Stafford GA; Henstenberg JD; Sharp GW; Weiland GA
    J Pharmacol Exp Ther; 1991 Aug; 258(2):652-62. PubMed ID: 1713965
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of oxodipine and elgodipine on (+)-[3H]-isradipine binding to cardiac and vascular membranes: cardiovascular selectivity.
    Rakotoarisoa L; Leprêtre N; Mironneau J; Galiano A; Mironneau C
    Fundam Clin Pharmacol; 1994; 8(6):546-52. PubMed ID: 7721232
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ca2+ channel inhibition by a new dihydropyridine derivative, S11568, and its enantiomers S12967 and S12968.
    Randle JC; Lombet A; Nagel N; Abraham C; Aptel H; Peglion JL; Renaud JF
    Eur J Pharmacol; 1990 Nov; 190(1-2):85-96. PubMed ID: 1706275
    [TBL] [Abstract][Full Text] [Related]  

  • 29. NZ-105, a new 1,4-dihydropyridine derivative: correlation between dihydropyridine receptor binding and inhibition of calcium uptake in rabbit aorta.
    Yamashita T; Masuda Y; Sakai T; Tanaka S; Kasuya Y
    Jpn J Pharmacol; 1991 Nov; 57(3):337-48. PubMed ID: 1667534
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacological, radioligand binding, and electrophysiological characteristics of FPL 64176, a novel nondihydropyridine Ca2+ channel activator, in cardiac and vascular preparations.
    Zheng W; Rampe D; Triggle DJ
    Mol Pharmacol; 1991 Nov; 40(5):734-41. PubMed ID: 1719369
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effects of strychnine on the regulation of voltage-dependent calcium channels by dihydropyridines in brain and heart.
    O'Neill SK; Bolger GT
    Pharmacol Biochem Behav; 1990 Apr; 35(4):833-40. PubMed ID: 1693213
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Selective antagonism of calcium channel activators by fluspirilene.
    Kenny BA; Fraser S; Kilpatrick AT; Spedding M
    Br J Pharmacol; 1990 Jun; 100(2):211-6. PubMed ID: 1696149
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of dihydropyridine calcium channel blocking drugs on rat brain muscarinic and alpha-adrenergic receptors.
    Thayer SA; Welcome M; Chhabra A; Fairhurst AS
    Biochem Pharmacol; 1985 Jan; 34(2):175-80. PubMed ID: 2981533
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A new Ca-antagonist, CD-349, binding to the Ca-channel of rat myocardium and brain and hog coronary artery.
    Muramatsu M; Fujita-Tominaga A; Tanaka M; Ishii Y; Aihara H
    Jpn J Pharmacol; 1988 Dec; 48(4):453-62. PubMed ID: 2854176
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SR 33557, a novel calcium entry blocker. II. Interactions with 1,4-dihydropyridine, phenylalkylamine and benzothiazepine binding sites in rat heart sarcolemmal membranes.
    Nokin P; Clinet M; Beaufort P; Meysmans L; Laruel R; Chatelain P
    J Pharmacol Exp Ther; 1990 Nov; 255(2):600-7. PubMed ID: 2147036
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacological in vitro studies of the new 1,4-dihydropyridine calcium antagonist lercanidipine.
    Guarneri L; Angelico P; Ibba M; Poggesi E; Taddei C; Leonardi A; Testa R
    Arzneimittelforschung; 1996 Jan; 46(1):15-24. PubMed ID: 8821512
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neuropharmacological characterization of voltage-sensitive calcium channels: possible existence of neomycin-sensitive, omega-conotoxin GVIA- and dihydropyridines-resistant calcium channels in the rat brain.
    Yamada K; Teraoka T; Morita S; Hasegawa T; Nabeshima T
    Jpn J Pharmacol; 1993 Dec; 63(4):423-32. PubMed ID: 8121077
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification, characterization, and photoaffinity labeling of the dihydropyridine receptor associated with the L-type calcium channel from bovine adrenal medulla.
    Murphy BJ; Rogers CA; Sunahara RK; Lemaire S; Tuana BS
    Mol Pharmacol; 1990 Feb; 37(2):173-81. PubMed ID: 2154669
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mechanism of vascular relaxation by thaligrisine: functional and binding assays.
    Tur R; Magraner J; Catret M; Elorriaga M; Ivorra MD; D'Ocon P; Bermejo A; Cabedo N; Cortes D; Anselmi E
    Life Sci; 2000 Aug; 67(13):1535-48. PubMed ID: 10983849
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of L-type Ca2+ channels in portal vein myocytes by the enantiomers of oxodipine.
    Baron A; Rakotoarisoa L; Leprêtre N; Mironneau J
    Eur J Pharmacol; 1994 Sep; 269(1):105-13. PubMed ID: 7828652
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.